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BACKGROUND: Cisplatin (CP) as an anticancer drug may affect the plasma glucose level while diabetic subjects are protected against CP-induced 
nephrotoxicity. In the current study, the role of dextrose 
hydration during CP therapy on CP-induced nephrotoxicity 
was evaluated. 
METHODS: Sixty-nine male and female rats were divided 
into 12 groups. The rats were hydrated with 15 mL/kg 
vehicle or different doses of  2%, 10% and 20% dextrose 
before and after 7.5 mg/kg CP administration. One week 
later, the biochemical and kidney function markers, and 
histology finding were determined. 
RESULTS: All the animals co-treated with CP and   20% 
dextrose, were dead during one week of the experiment. 
Administration of CP alone increased kidney tissue damage 
score (KTDS) and kidney weight (KW). It also elevated 
the blood urea nitrogen (BUN) and BUN-creatineine ratio 
(BUN/Cr) levels in the serum. In addition, CP decreased body 
weight and  creatinine (Cr) clearance (ClCr) significantly in 
both male and female rats (p<0.05). However, 2% and 10% 
dextrose did not alter the mentioned parameters in male, 
but 10% dextrose supplement increased the serum levels of 
BUN, Cr and BUN/Cr ratio, KW and KTDS significantly in 
female rats (p<0.05).
CONCLUSION: Our data suggest that not only do not 
support the nephro-protective role of dextrose hydration 
during CP therapy, the dextrose hydration can act as risk 
factor to promote CP-induced nephrotoxicity in female rats. 
Prohibition of high carbohydrate (glucose) diet during CP 
therapy is recommended.
KEywORDS: cisplatin, nephrotoxicity, dextrose, rat, 
gender
Indones Biomed J. 2019; 11(2): 136-44 
Abstract
Introduction
Cisplatin (CP) has been used widely in clinic for solid tumor 
chemotherapy; however one of the side effects of CP is 
nephrotoxicity which limits its clinical use. The CP-induced 
nephrotoxicity was reported to be gender related (1-4), and 
antioxidants supplements may attenuate the side effect of 
nephrotoxicity (1,5-9). The experimental findings also 
indicated that the sex hormone, estrogen, affects the CP-
induced nephrotoxicity.(10-13) In addition, this female sex 
hormone may promote CP-induced nephrotoxicity (11) or 
limit the protective effect of antioxidant against CP-induced 
kidney injury (13). 
 CP may decrease glucose uptake in ovarian cancer 
cell, and it disappears the membrane localization of 
glucose transporter 1.(14) In addition, CP itself may induce 
hyperglycemia and glucose intolerance (15), and this 
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impairment maybe related to insulin secretion deficiency.
(16) Previously, it was reported that in diabetic animals 
were protected against CP-induced nephrotoxicity.(17-20) 
Diabetes disturbs the active transport of proximal tubule 
and reduce CP accumulation in the tubule (21), therefore, 
it protects the kidney against CP-induced nephrotoxicity. 
However, among the factors affecting CP-induced 
nephrotoxicity, the role of glucose is not well clear.  
 Usually, based on the treatment guideline, the 
candidate patients for CP therapy must be hydrated during 
CP administration.(22)  If hyperglycemia is the main cause 
of kidney protection against CP-induced nephrotoxicity 
in diabetic subjects, it is expected that the patients who 
hydrated with high glucose solution (instead saline) would 
be protected against CP-induced nephrotoxicity. On the other 
hand, practically it is observed that many of the patients who 
are candidate for CP therapy have an appetite to eat cookie 
or high sweet diets during the CP administration time in the 
hospital. 
 Collectively, there are 2 facts. First, CP  administration 
is accompanied with side effect of nephrotoxicity gender 
dependently.(1-4) Secondly, the diabetic subjects are 
protected against CP-induced nephrotoxicity.(17-20) One 
explanation for this difference is related to the dose of 
glucose concentration which is different in normal and 
diabetic conditions. Therefore, one question was raised, 
is high dose of glucose uptake during CP therapy could 
protect the kidney against CP-induced nephrotoxicity or 
not, and what is the role of gender? In order to answer these 
questions, male and female rats were subjected to hydrate 
with different doses of dextrose solution during CP therapy, 
and they were compared with control group. 
Methods
The protocol of this research was considered and approved 
by the Ethics Committee of Isfahan University of Medical 
Sciences (IR.MUI.REC.1397.2.055). 
Drugs
The CP and dextrose were purchased from Malan (Athens, 
Greece) and Shahid Ghazi Pharmaceutical Co (Tabriz, Iran).
Experimental Groups
This research was conducted on 69 male and female Wistar 
rats in 12 groups (6 groups of male and 6 groups of female 
rats). Group 1 and 7 (vehicle groups) were consisted of 5 
male and 6 female rats. Eleven rats were subjected to 3 
treatments. The first treatment of vehicle (saline, 15 mL/
kg, intraperitoneally) was applied at the beginning of 
experiment. The second treatment of vehicle (0.5-1 mL/rat) 
was applied 60 min post the first treatment. Finally, the third 
treatment of vehicle (saline, 15 mL/kg, intraperitoneally) 
was applied 60 min post the second treatment. 
 Group 2 and 8 were the dextrose 10% groups, which 
were consisted of 5 male and 6 female rats. They received 
the same regimen as groups 1 and 7, except they were given 
dextrose 10% (15 mL/kg, intraperitoneally) instead of 
vehicle (saline) for the first and third treatments.
 Group 3 and 9, or known as CP groups, were consisted 
of 5 male and 6 female rats, which received the same 
regimen as group 1 and 7, except they were given CP (7.5 
mg/kg, intraperitoneally), instead of vehicle (saline) for the 
second treatment.
 Group 4 and 10, the CP + dextrose 2% groups, were 
consisted of 6 male and  6 female. These 12 rats were also 
subjected to 3 treatments. The first treatment of dextrose 
2% (15 mL/kg, intraperitoneally) was applied at the 
beginning of experiment. The second treatment of CP (7.5 
mg/kg, intraperitoneally) was applied 60 min post the first 
treatment, and the third treatment of dextrose 2% (15 mL/
kg, intraperitoneally) was applied 60 min post the second 
treatment. 
 Group 5  and 11, the CP + dextrose 10% groups, were 
consisted of 6 male and  6 female rats, which were treated 
just like groups 4 and 10, except they received 15 mL/kg of 
dextrose 10% instead of dextrose 2% for the first and third 
treatments.
 Group 6 and 12, CP + dextrose 20% groups, were 
consisted of 5 male and 6 female rats, which were treated as 
groups 4 and 10, except they received 15 mL/kg of dextrose 
20% instead dextrose 2% for the first and third treatments. 
Survival Time Determination
The animals were kept in standard cages with free access to 
water and food. All the animals were observed continually 
(3-4 times a day) and weighted in the first and 8th days of 
experiment. The mortality rate for each animal group was 
recorded daily. 
Urine, Blood and Kidney Tissue Samples Collections
The remained survived animals until the 8th day were 
subjected to place in metabolic cages for 5 hours before 
sacrifice for urine collection. The total amount of urine 
collection in each animal was measured precisely and 
reported as microliter per minute per gram kidney tissue. 
Then, blood samples were obtained and the animals 
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sacrificed humanly. The kidneys were removed rapidly 
and weighted. The tissues were fixed in formalin 10% to 
perform histological investigation using hematoxylin and 
eosin (H&E) staining. The kidney tissue damage score 
(KTDS) was recorded by two pathologist who were blinded 
to study protocol. The score was assigned from 1 to 4 based 
on intensity of tissue damage while zero was considered as 
normal.  
Biochemical Parameters Measurements
The levels of blood urea nitrogen (BUN) and creatinine 
(Cr), were determined using quantitative diagnostic kits 
(Pars Azmoon, Tehran, Iran). The malondialdehyde (MDA) 
levels in the serum and kidney tissue were measured by 
the manual method. The serum and kidney tissue levels of 
nitrite (stable nitric oxide (NO) metabolite) were measured 
using Griess method. The levels of sodium (Na) in serum 
and urine were determined using flame photometer assay.
Kidney Function Parameters Measurements
The Cr clearance (ClCr) was determined using clearance 
formula as; ClCr = UF * UCr/ PCr where UF, UCr and PCr 
were assigned for urine flow rate, urine Cr concentration 
and serum level of Cr. The Na filtration rates (FNa) and 
Na excretion rate (ENa) were calculated by [ClCr x serum 
concentration of Na] and [UF x urine concentration of Na] 
respectively.
Statistical Analysis
Data were reported as mean±SEM. The ANOVA and Dunnet 
test as post hoc were applied for comparison between the 
groups. The survival time and KTDS between the groups 
were compared by non-parametric tests of  Kruskal-
Wallis and  Mann-Whitney U.  The statistical p-value was 
significant when it was less than 0.05.
Animal’s Survival Time
The data for animal’s survival time are tabulated in Table 1. 
The entire male (survival time = 4.8±0.4 days) and female 
(survival time = 4.0±0.0 days) animals treated with CP + 
extrose 20% expired during the experiment and no animals 
were survived for the last day of experiment (sacrifice day). 
Therefore no data were reported here for these groups. No 
animals were died in the control groups of male (groups 
1-3) and female (groups 7-9) rats. However, 3 male and 2 
female animals that treated with CP + dextrose 2%-10% 
Results
were expired during the experiment before sacrifice day 
(Table 1). 
Body and Kidney weights
The body weight percentage change (∆W%) and normalized 
kidney weight (KW) in vehicle, dextrose 10% or CP alone 
(male’s group 1-3 and female’s group 7-9) treated groups 
were compared to determine the effect CP or dextrose alone 
administration (Table 2A). The results indicated that CP 
increased the absolute ∆W and KW significantly (p<0.05) 
in both genders.
 The animals treated with CP alone also were compared 
with the animals co-treated with CP and dextrose (Figure 
1A). Co-administration of CP and dextrose did not attenuate 
the KW when compared with CP alone treated group (Figure 
1A). Instead, in the female rats, co-administration of CP and 
dextrose 10% not only attenuate the KW but also increased 
the KW (1.36±0.16 g) significantly when compared with CP 
alone (0.94±0.04 g) treated group (p<0.05) (Figure 1A).
Biochemical Parameters
The serum levels of BUN, Cr and BUN/Cr ratio  in vehicle, 
dextrose 10% or CP alone treated groups (male’s group 1-3 
and female’s group 7-9) were compared to determine the 
effect CP or dextrose alone administration (Table 2B). The 
results indicated that CP increased the above parameters 
(except the serum level of Cr in female) significantly 
(p<0.05).
 The animals treated with CP alone also were compared 
with the animals co-treated with CP and dextrose (Figure 
1B). Co-treatment of CP and dextrose did not attenuate 
the serum level of BUN, Cr and BUN/Cr ratio in male. 
However, in female rats, the co-administration of CP and 
dextrose 10% increased the serum level of BUN (92.4±35.9 
mg/dL vs. 28.4±1.8 mg/dL, p<0.05), Cr (1.6±0.4 mg/dL vs. 
0.75±0.05 mg/dL, p<0.05) and BUN/Cr ratio (52.7±7.3 vs. 
38.2±2.0, p<0.05) significantly) when compared with CP 
alone treated group.
 The serum and kidney tissue levels of nitrite and MDA 
in vehicle, dextrose 10% or CP alone treated groups (male’s 
group 1-3 and female’s group 7-9) also were compared to 
determine the effect CP or dextrose alone administration 
(Table 2C). The results indicated that CP altered the serum 
and kidney levels of nitrite and the serum level of MDA 
significantly (p<0.05) in male groups. 
 The animals treated with CP alone also were compared 
with the animals co-treated with CP and dextrose (Figure 
1C). The serum and kidney tissue levels of MDA in male 
rats were not different statistically between CP alone treated 
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Parameter Gender Vehicle Dextrose 10% CP P ANO VA
Male -1.0±1.0 3.7±1.0* -19.0±1.2* <0.0001
Female 1.9±0.9 -1.8±1.2 -9.0±3.4* 0.008
Male 0.68±0.02 0.67±0.02 1.06±0.04* <0.0001
Female 0.76±0.02 0.83±0.02 0.94±0.04* 0.002
Parameter Gender Vehicle Dextrose 10% CP P ANO VA
Male 17.94±0.6 25.14±0.7 43.1±6.6* 0.002
Female 20.48±1.14 20.71±0.73 28.4±1.8* 0.001
Male 0.87±0.06 0.65±0.03* 1.25±0.07* <0.0001
Female 0.72±0.02 0.74±0.01 0.75±0.05 0.83
Male 20.9±1.6 38.7±1.9* 33.6±4.2* 0.002
Female 28.4±2.1 27.9±1.4 38.2±2.0* 0.002
Parameter Gender Vehicle Dextrose 10% CP P ANO VA
Male 9.23±1.07 11.43±0.82 17.89±2.10* 0.003
Female 11.04±1.55 8.43±0.67 13.19±2.83 0.24
Male 0.15±0.02 0.19±0.01 0.10±0.01* 0.024
Female 0.18±0.03 0.18±0.01 0.16±0.02 0.85
Male 0.19±0.17 0.25±0.14 1.91±0.89* 0.06
Female 2.31±0.47 1.68±0.25 3.63±1.26 0.23
Male 55.34±1.71 72.96±15.04 48.88±3.66 0.19
Female 94.10±10.98 92.63±21.15 71.10±4.24 0.44
Kidney Nitrite (µmol/g)
Serum MDA (µmol/L)
Kidney MDA (nmol/g)
∆W (%)
KW (g)/100g BW
BUN (g/dL)
Cr (g/dL)
BUN/Cr
Serum Nitrite (µmol/L)
A
B
C
Table 2. The effects of dextrose 10% and CP administration against vehicle on body and kidney weight (A), serum levels of BUN, 
Cr, BUN/Cr ratio (B), and serum and kidney levels of nitrite and MDA (C).
The p-value was obtained by ANOVA, and the star (*) indicates significant differences (p<0.05) from vehicle group using Dunnet test.  CP: 
cisplatin, ∆W; weight change, KW: kidney weight, BUN: blood urea nitrogen, Cr: creatinine.
group and co-treated of CP and dextrose groups. However, 
in female rats the serum and kidney tissues levels of MDA 
were decreased in co-treated of CP and dextrose groups 
when compared with CP alone treated rats (Figure 1C), but 
the decrease was significant for the serum level of MDA in 
co-treated group of CP and dextrose 2% (0.60±0.15 µmol/L 
vs. 3.6±1.3 µmol/L, p<0.05), and the decrease for the kidney 
tissue level of MDA was significant in co-treated group of 
CP and dextrose 10% (37.6±1.4 nmol/g tissue vs. 71.1±4.2 
nmol/g tissue, p<0.05). 
 The serum levels of nitrite decreased (significantly), 
and the tissue levels of nitrite were increased (insignificantly) 
in co-treated of CP and dextrose male rats when compared 
with CP alone treated group (Figure 1C). Such observation 
was not seen in female rats but co-treatment of CP and 
dextrose 2% increased the kidney tissue level of nitrite 
statistically (p<0.05).   
Kidney Function Parameters
The UF, ClCr, FNa, ENa and Na excretion fraction (%) in 
vehicle, dextrose 10% or CP alone treated groups (male’s 
group 1-3 and female’s group 7-9) were compared to 
determine the effect CP or dextrose alone administration 
(Table 3A). The ClCr and FNa  in both genders, ENa 
in female and Na excretion fraction (%) in male were 
significantly different between CP treated rats and vehicle 
treated group (p<0.05).
 The animals treated with CP alone also were compared 
with the animals co-treated with CP and dextrose (Figure 
2). The results of renal function markers; UF, ClCr, FNa, 
ENa and percentage of Na excretion fraction are presented 
in Figure 2. They are indicated that co-administration of CP 
and dextrose compared to CP alone did not alter the renal 
function markers neither in male nor in female rats. Actually 
in female, all the above markers in co-treated group of CP 
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Figure 1. Characteristic difference between male and female rats of survived animals in the experimental groups. A: percentage 
of weight change (%) and kidney weight (KW) (g) per 100 g of body weight (BW). B: serum levels of blood urea nitrogen (BUN) (mg/
dL), creatinine (Cr) (mg/dL) and BUN/Cr ratio. C: serum (µmol/L) and kidney tissue (µmol/g tissue) levels of malondealdehyde (MDA) 
and nitrite for survived animals in the experimental groups. The CP, CP+DS2% and CP+DS10% indicate the groups treated with cisplatin, 
cisplatin plus dextrose 2%  and cisplatin plus dextrose 10%, respectively. The p-value was obtained by ANOVA. The star (*) indicates 
significant differences (p<0.05) from CP using Dunnet test.
and dextrose 10% were decreased when compared with 
CP alone treated group, however these change were not 
statistically significant (Figure 2).
Kidney Histology Findings
The KTDS  in vehicle, dextrose 10% or CP alone treated 
groups (male’s group 1-3 and female’s group 7-9) were 
compared to determine the effect CP or dextrose alone 
administration (Table 3B). The results indicated that CP 
increased the KTDS significantly (p<0.05) in both genders. 
The  animals  treated  with  CP  alone  also  were  compared 
with the animals co-treated with CP and dextrose (Figure 
3). The KTDS did not alter in co-treated of CP and dextrose 
male rats compared to CP alone treated group, however in 
female rats, the KTDS was increased significantly in co-
treated with CP and dextrose 10%  group compared to CP 
alone treated group (3.3±0.2 vs. 2.3±0.2; p<0.05). More 
tubular tissue damage was observed in female rats treated 
with CP and dextrose 10% compared to the CP alone treated 
animals. 
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Table 3. The effects of dextrose 10% and cisplatin (CP) administration against vehicle on  urine flow (UF), creatinine clearance 
(ClCr), sodium (Na) filtration rate (FNa), Na excretion rate (ENa) and percentage of Na excretion fraction (%) (A), and kidney 
tissue damage score (KTDS) (B).
Parameter Gender Vehicle Dextrose 10% CP P ANOVA
Male 2.9±0.7 5.05±1.0 4.50±0.8 0.21
Female 5.3±0.7 2.37±0.4* 4.01±1.0 0.04
Male 732.6±125.1 951.9±75.3 197.8±26.6* <0.0001
Female 1148.3±144.6 706.8±100.8* 510.1±142.0* 0.011
Male 120.6±22.9 157.9±9.4 33.8±4.8* <0.0001
Female 172.9±23.2 115.9±15.4 92.5±25.8* 0.05
Male 0.46±0.15 1.16±0.14* 0.59±0.15 0.014
Female 0.99±0.12 0.35±0.08* 0.35±0.07* <0.0001
Male 0.36±0.07 0.74±0.09 1.67±0.28* 0.001
Female 0.63±0.11 0.41±0.18 1.75±1.45 0.5
Parameter Gender Vehicle Dextrose 10% CP P Kruskal-Wallis
Male 0.8±0.2 0.6±0.2 3.2±0.4* <0.0001
Female 1±0.3 0.7±0.3 2.3±0.2* <0.0001
KTDS
UF (µL/mim/g)
ClCr (µL/mim/g)
FNa (µmole/mim/g)
ENa (µmole/mim/g)
Na Excretion Fraction (%)
A
B
The p-value  in part A was obtained by ANOVA, and the star (*) indicates significant differences (p<0.05) from vehicle group using Dunnet 
test.  The p-value  in part B was obtained Kruskal–Wallis, and the star (*) indicates significant differences (p<0.05) from vehicle group 
using Mann–Whitney U test. CP: cisplatin; UF: urine flow rate; ClCr: Creatinine clearance; FNa: sodium filtration rate;  ENa: sodium 
excretion rate; KTDS: kidney tissue damage score.
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Figure 2. The urine flow (UF), creatinine clearance (ClCr), sodium (Na) filtration rate (FNa), Na excretion rate (ENa) and percentage 
of Na excretion fraction in cisplatin, cisplatin plus dextrose 2%  and cisplatin plus dextrose 10%  treated groups, respectively. The 
p-value was obtained by ANOVA. The star (*) indicates significant differences (p<0.05) from CP using Dunnet test. CP: cisplatin; DS: 
dextrose. The unit for UF=µL/mim/g tissue, ClCr=µL/mim/g tissue, ENa=µmol/mim/g tissue, FNa=µmol/mim/g tissue; FNa fraction=%.
Discussion
The purpose of this study was to determine the possible 
protective role of dextrose hydration during CP therapy 
against CP induced nephrotoxicity. Our hypothesis 
was rejected while dextrose promoted CP-induced 
nephrotoxicity, and the major findings of this research 
revealed that dehydration with dextrose during CP therapy 
acts as risk factor to promote kidney toxicity. 
 No animals were survived when dextrose 20% was 
accompanied with CP, possibly due to toxic effect of high 
dose of dextrose. The animals weight loss was observed in 
the all survived animals treated with CP which was expected 
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p=0.77
p=0.04
Fig 3. The kidney tissue damage score (KTDS) (right panel) for survived animal in the experimental groups. The CP, CP+DS2% 
and CP+DS10% indicate the groups treated with cisplatin, cisplatin plus dextrose 2%  and cisplatin plus dextrose 10%, respectively. The 
p-value was obtained by Kruskal–Wallis test. The star indicates significant differences (p<0.05) from CP using Mann-Whitney U test.White 
bar: 0.25 mm x 1.0 mm.
as observed in other studies.(1-4) In addition the elevations 
of the serum levels of BUN and Cr and KW are associated 
with increase of kidney damage after CP administration (4), 
and our results indicated that dextrose 10% elevated these 
parameters in female gender. It seems these alterations are 
related to the decrease of ClCr (or glomerular filtration rate) 
in female rats treated with CP and dextrose 10% (Figure 
2). These findings in female rats also are in agreement with 
pathology data and KTDS (Figure 3). 
 It has been proposed that diabetes protects the kidneys 
against CP administration (18-20), and the degree of 
protection depends on degree of hyperglycemia. Previous 
study reported that the diabetic state could protect that 
kidney against CP-induced nephrotoxicity, and the kidney 
toxicity would be higher if the hyperglycemia was corrected 
by insulin.(20) The vacuolated cells, tubular dilation and 
necrosis-induced by CP administration in rat. However 
these tissue damages were attenuated in diabetic state.(20) 
One mechanism is related to kidney drug accumulation, 
because in diabetic state, the reduction of platinum 
accumulation in the kidney is occured.(23) One study 
demonstrated that hyperglaycemia reduction by insulin 
treatment in diabetic rats may not protect the kidney against 
CP-induced nephrotoxicity.(18)  Therefore, it seems that an 
interaction between glucose concentration and CP exists 
as the membrane localization of glucose transporter 1 may 
disappear by CP therapy.(14)
 In our study, it seems that the high dose of dextrose 
administration was toxic in CP treated rats, and possibly 
administration of dextrose induces insulin secretion in 
non-diabetics rats which causes platinium accumulation in 
renal cortex.(18) Therefore, accumulation of CP in kidney 
promotes nephrotoxicity as shown by increase in kidney 
weight and Cr level increase in dextrose treated rats. Other 
study demonstrated that the serum level of insulin was 
increased after 3 days post CP injection,  and CP-induced 
hyperglycemia and glucosuria precede CP induced acute 
renal failure.(24) 
Conclusion
Collectively, our data not only did not support the nephro-
protective role of dextrose hydration during CP therapy but 
also indicated that dextrose diets during CP therapy act as 
risk factor to promote CP-induced nephrotoxicity in female 
rats. Further studies are needed to find the exact mechanism.
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